Pliant Therapeuticsの空売り状況は、投資家がPliant Therapeuticsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Pliant Therapeutics (NASDAQ:PLRX) 株価情報, 空売り情報

Pliant Therapeutics

Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.

Pliant Therapeutics Inc

<a href="https://www.politico.com/news/2025/04/22/white-house-is-close-on-japan-india-agreements-but-expect-them-to-be-light-on-specifics-00302762">https://www.politico.com/news/2025/04/22/white-house-is-close-on-japan-india-agreements-but-expect-them-to-be-light-on-specifics-00302762</a>

News

General

'White House Is 'Close' On Japan, India Tariff Agreements — But Expect Them To Be Light On Specifics'- Politico

Barclays analyst Jeffrey Bernstein maintains Performance Food Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFGC#NYSE">PFGC</a>) with a Overweight and lowers the price target from $102 to $95.

Price Target

Analyst Ratings

PFGC

Barclays Maintains Overweight on Performance Food Gr, Lowers Price Target to $95

Jones Trading analyst Jason Weaver maintains AGNC Investment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGNC#NASDAQ">AGNC</a>) with a Buy and lowers the price target from $10.25 to $9.5.

AGNC

Jones Trading Maintains Buy on AGNC Investment, Lowers Price Target to $9.5

WIIM

HUTCHMED shares are trading higher after the company announced it completed enrollment of the registration phase of its Phase II trial of savolitinib in gastric cancer patients with MET amplification.

Barclays analyst Jeffrey Bernstein maintains McDonald's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>) with a Overweight and lowers the price target from $350 to $347.

Barclays Maintains Overweight on McDonald's, Lowers Price Target to $347

Global

Economics

Trading Ideas

S&P Futures See Volume To The Downside, Traders Circulate Unconfirmed Report From Reuters Saying U.S. Treasury Secretary Bessent Says China Negotiations Will Be A 'Slog', Describing Current Bilateral Trade Situation As An Embargo

Chinese CMOC Group, the world's largest producer of cobalt, has announced an all-cash acquisition of Canadian development-stage mining company Lumina Gold Corp (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/LMGDF#OTCQB">LMGDF</a>), valued at C$581 million (around $420 million).
Upon acquisition, CMOC will gain control over the Cangarejos gold-copper project, one of <a target="_blank" href="https://www.benzinga.com/topic/gold" rel="noreferrer noopener">the world's largest undeveloped gold assets</a> located in southwest Ecuador.
"After advancing the Cangrejos project for over ten years and taking it from no defined resources to being poised to be one of the largest gold projects globally, the Lumina Group is excited for the transition of the Cangrejos project to CMOC," <a target="_blank" href="https://luminagold.com/lumina-gold-announces-acquisition-by-cmoc-for-c581-million/" rel="noreferrer noopener">said</a> Lumina CEO Marshall Koval.
"We look forward to working with CMOC and all existing stakeholders to ensure the successful future development of the project."
According to Lumina's <a target="_blank" href="https://wp-luminagold-2024.s3.ca-central-1.amazonaws.com/media/2024/02/26213258/Cangrejos-Project-NI-43-101-Technical-Report-on-PFS-F.pdf" rel="noreferrer noopener">2023 prefeasibility study</a>, Cangrejos is expected to operate for 26 years, with an average annual production of 371,000 ounces of gold and 41 million pounds of copper. About 80% of the project's revenue is expected to come from gold, with average gold-equivalent production projected at 469,000 ounces annually.
The project's design is scalable, starting at 30,000 tons per day and increasing to around 80,000 tons per day by the seventh year of production.
The study places the initial capital cost at US$925 million, with an after-tax NPV of US$2.2 billion and an internal rate of return of 17.2%, based on base-case metal prices. All-in sustaining costs are estimated at US$671/oz, net of by-product credits.
The acquisition offers C$1.27 per Lumina share, representing a 71% premium over Lumina's 20-day volume-weighted average and a 41% premium to the company's April 17 closing price.
The transaction, structured through a court-approved plan of arrangement, has already garnered support from shareholders holding 52.3% of Lumina's outstanding shares.
The agreement includes standard deal protections, such as a C$23.3 million termination fee payable by Lumina under certain circumstances and a C$2.8 million expense reimbursement clause in CMOC's favor. Lumina retains a fiduciary out, enabling it to consider superior proposals, subject to CMOC's right to match.
CMOC will also purchase unsecured convertible notes to provide US$20 million in interim financing to Lumina. These notes mature in April 2026, carry a 6% annual interest rate, and convert into Lumina shares at C$1.00 per share. This financing is intended to support ongoing development at Cangrejos before the transaction's closing.
The transaction is expected to be completed in the third quarter of 2025, subject to shareholder, court, and regulatory approvals. Once finalized, Lumina Gold will be delisted from the TSX Venture Exchange and cease to be a reporting issuer under Canadian securities laws.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/04/44903750/gold-price-soars-to-record-highs-eyes-best-2-month-rally-since-2011-on-blockbuster-etf-buying" target="_blank" rel="noreferrer noopener">Gold Price Soars To Record Highs, Eyes Best 2-Month Rally Since 2011 On Blockbuster ETF Buying</a></li>
</ul>
Photo courtesy: Shutterstock

Equities

Latin America

Financing

Commodities

Legal

Markets

LMGDF

China's CMOC Group Acquires Lumina Gold For $420 Million

Bernstein analyst Stacy Rasgon maintains Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) with a Market Perform and lowers the price target from $125 to $95.

Bernstein Maintains Market Perform on Advanced Micro Devices, Lowers Price Target to $95

Barclays analyst Jeffrey Bernstein maintains Jack In The Box (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JACK#NASDAQ">JACK</a>) with a Equal-Weight and lowers the price target from $40 to $24.

JACK

Barclays Maintains Equal-Weight on Jack In The Box, Lowers Price Target to $24

Regeneron Pharmaceuticals, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) on Tuesday announced a significant expansion of its manufacturing capacity through a new agreement with FUJIFILM Diosynth Biotechnologies to manufacture and supply bulk drug products of Regeneron&#8217;s commercial biologic medicines at their Holly Springs, <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">North Carolina, campus</a>.
Regeneron, already one of the world&#8217;s largest biologics manufacturers, will nearly double its U.S. large-scale manufacturing capacity by accessing Fujifilm&#8217;s <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g44916999/regeneron-announces-new-investment-in-manufacturing-of-its-industry-leading-biologic-medicines" rel="noreferrer noopener">new biopharmaceutical facility</a>.
With technology transfer beginning immediately and a 10-year term, the total investment is estimated to exceed $3 billion.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44870253/fda-accepts-priority-review-of-regenerons-flagship-drug-eylea-hd-for-expanded-use" rel="noreferrer noopener">FDA Sets The Countdown: Regeneron&#8217;s Eylea HD Could Be Headed For Major Expansion</a>
&#8220;Regeneron is an American success story, with over 80 percent of our workforce and assets in the U.S. and all of our FDA-approved medicines invented in our New York laboratories&#8230;&#8221; said Leonard Schleifer, Board co-Chair, president and CEO of Regeneron.
&#8220;FUJIFILM Diosynth Biotechnologies will be bringing additional capacity online in 2025, 2026 and beyond as it completes the current $7 billion of expansion projects underway in both Europe and United States,&#8221; &nbsp;said Toshihisa Iida, director, corporate vice president, general manager of Life Sciences Strategy Headquarters and Bio-CDMO Division,<a href="https://www.benzinga.com/pressreleases/25/04/b44917015/fujifilm-diosynth-biotechnologies-and-regeneron-sign-a-10-year-u-s-manufacturing-agreement-valued-" target="_blank" rel="noreferrer noopener"> FUJIFILM Corporation, Japan</a>.
Regeneron continues to invest heavily in its New York State operations. An approximately $3.6 billion expansion of its Tarrytown campus is underway, creating 1,000 full-time, high-skill jobs and expanding research, preclinical manufacturing, and support facilities.
In addition, the company is constructing a brand new fill/finish manufacturing facility in Rensselaer, New York. It has acquired an over 1 million-square-foot property in Saratoga Springs, New York, for production support activities and, potentially, additional manufacturing capacity.
Regeneron has added more than 7,000 jobs in the past five years, most of which are high-paying R&amp;D and manufacturing jobs based in the U.S.
Regeneron&#8217;s ongoing and planned investments in New York and North Carolina infrastructure and manufacturing are expected to total more than $7 billion.
On Friday, the U.S. Food and Drug Administration (FDA) issued a complete response letter (CRL) regarding the supplemental Biologics License Application (sBLA) for the addition of extended dosing intervals (up to every 24 weeks) for Regeneron&#8217;s Eylea (aflibercept) Injection 8 mg <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g44886470/regeneron-provides-update-on-eylea-hd-aflibercept-injection-8-mg-supplemental-biologics-license-ap" rel="noreferrer noopener">across all approved indications</a>.
The CRL did not identify any issues with the safety or efficacy of Eylea HD in its approved indications and dosing regimens. The FDA did not agree with Regeneron&#8217;s proposal to add additional extended dosing intervals (greater than every 16 weeks, which is the maximum dosing interval currently indicated in the label). Regeneron is evaluating the FDA&#8217;s decision.
On Friday, the FDA approved Regeneron and Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) partnered Dupixent&nbsp;(dupilumab) for adults and adolescents aged 12 years and older with chronic spontaneous urticaria (CSU) who remain symptomatic despite histamine-1 (H1) <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g44884755/dupixent-dupilumab-approved-in-the-u-s-as-the-first-new-targeted-therapy-in-over-a-decade-for-chro" rel="noreferrer noopener">antihistamine treatment</a>.
Price Action: REGN stock is up 4.2% at $585.25 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44922218/lockheed-martin-posts-strong-q1-says-maintained-2025-guidance-doesnt-include-tariff-impact" target="_blank" rel="noreferrer noopener">Lockheed Martin Does Not Alter Annual Outlook To Price Tariff Impact Yet Amid Recent CFO Change</a></li>
</ul>
Photo: Shutterstock

Biotech

Large Cap

Health Care

Movers

REGN

Regeneron Expands US Manufacturing With $3 Billion Fujifilm Deal

Dollar Tree, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) and Dollar General Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) shares may be breaking out. This action suggests a continued move higher.
This is why our technical analysis team has picked them as our Stocks of the Day.
Stocks trend higher due to an imbalance in supply and demand. If there are more shares to be bought than for sale, buyers need to outbid each other. They know sellers will go to whoever wants to pay the highest price. This action forces the shares into an uptrend.
At resistance levels, there are as many or possibly even more shares for sale than there are to be bought. This is why rallies end or pause when they reach these levels.
Sometimes, stocks roll over and trend lower after they reach resistance. This happens when some traders and investors who created the resistance with their sell orders become anxious.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="563" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/22130949/DLTR-1024x563.png" alt="" class="wp-image-882505" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/22130949/DLTR-1024x563.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/22130949/DLTR-300x165.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/22130949/DLTR-768x422.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/22130949/DLTR.png 1507w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="569" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/22131024/DG-1024x569.png" alt="" class="wp-image-882506" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/22131024/DG-1024x569.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/22131024/DG-300x167.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/22131024/DG-768x427.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/22131024/DG.png 1501w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Also: <a href="https://www.benzinga.com/government/regulations/25/04/44926902/imf-slashes-us-growth-outlook-as-trump-tariffs-bite-raises-recession-odds-to-40">IMF Slashes US Growth Outlook As Trump Tariffs Bite, Raises Recession Odds To 40%</a>
They know buyers will go to whoever sells them shares at the lowest price. These anxious sellers don't want to miss out on the trade, so they reduce the prices they are willing to sell their shares.
Other anxious sellers see this and do the same thing. This can force the stock into a downtrend.
But sometimes, when a stock reaches a resistance level, buyers overpower the sellers and push the price higher. When this happens, traders say that it is a breakout.
As you can see on the charts of Dollar General and Dollar Tree, they may be breaking out.
Breakouts tend to be bullish. They show that the investors and traders who created the resistance with their sell orders have finished or canceled their orders.
With this large amount of supply taken out of the market, the stage could be set for a move higher. Those who wish to buy will be forced to outbid each other again to draw the sellers back in.
This could result in another bidding war that forces the price even higher. It may be about to happen with both of these stocks.
Read Next: • <a href="https://www.benzinga.com/25/04/44925313/tesla-q1-earnings-preview-shareholders-analysts-want-answers-on-guidance-tariffs-fsd-and-more">Tesla Q1 Earnings Preview: Shareholders, Analysts Want Answers On Guidance, Tariffs, FSD And More</a>

Photos: Dollar Tree via Shutterstock, Dollar General courtesy Dollar General

Technicals

DLTR

Stocks Of The Day: Will Dollar Tree, Dollar General Breakout?

Barclays analyst Dan Levy maintains First Watch Restaurant Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWRG#NASDAQ">FWRG</a>) with a Overweight and raises the price target from $21 to $24.

FWRG

Barclays Maintains Overweight on First Watch Restaurant Gr, Raises Price Target to $24

Barclays analyst Jeffrey Bernstein maintains Dutch Bros (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BROS#NYSE">BROS</a>) with a Overweight and lowers the price target from $94 to $76.

BROS

Barclays Maintains Overweight on Dutch Bros, Lowers Price Target to $76

Vertiv Holdings shares are trading higher after the company announced a collaboration with Nvidia and iGenius to deploy Colosseum, one of the world's largest  AI data centers.

Bernstein analyst Stacy Rasgon maintains Intel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) with a Market Perform and lowers the price target from $25 to $21.

INTC

Bernstein Maintains Market Perform on Intel, Lowers Price Target to $21

Barclays analyst Jeffrey Bernstein maintains Domino's Pizza (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NASDAQ">DPZ</a>) with a Underweight and raises the price target from $420 to $425.

Barclays Maintains Underweight on Domino's Pizza, Raises Price Target to $425

<h3>Gainers</h3>
<ul>
<li>Innventure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INV#NASDAQ">INV</a>) stock increased by 27.8% to $4.6 during Tuesday's regular session. The company's market cap stands at $216.6 million. </li>
<li>Triller Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILLR#NASDAQ">ILLR</a>) stock moved upwards by 25.24% to $1.29. The company's market cap stands at $195.5 million. </li>
<li>Open Lending (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPRO#NASDAQ">LPRO</a>) stock rose 17.64% to $1.0. The company's market cap stands at $119.7 million. </li>
<li>AGM Group Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGMH#NASDAQ">AGMH</a>) stock rose 16.54% to $0.03. The market value of their outstanding shares is at $1.3 million. </li>
<li>Coincheck Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNCK#NASDAQ">CNCK</a>) stock increased by 15.61% to $7.0. The market value of their outstanding shares is at $915.0 million. </li>
<li>Eason Technology (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/DXF#AMEX">DXF</a>) shares rose 14.89% to $8.1. The company's market cap stands at $1.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Highest Performances (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HPH#NASDAQ">HPH</a>) shares declined by 17.1% to $6.9 during Tuesday's regular session. The company's market cap stands at $1.7 billion. </li>
<li>SHF Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHFS#NASDAQ">SHFS</a>) stock declined by 11.44% to $3.71. The market value of their outstanding shares is at $10.3 million. </li>
<li>MicroSectors FANG Index -3X Inverse Leveraged ETNs due January 8, 2038 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNGD#NYSE">FNGD</a>) stock fell 10.02% to $15.99. </li>
<li>Santech Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STEC#NASDAQ">STEC</a>) stock fell 9.91% to $0.95. The company's market cap stands at $26.7 million. </li>
<li>Broadway Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BYFC#NASDAQ">BYFC</a>) shares fell 8.99% to $6.28. The company's market cap stands at $57.2 million. </li>
<li>Cheche Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCG#NASDAQ">CCG</a>) shares declined by 7.83% to $0.94. The market value of their outstanding shares is at $78.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-financial-services-stocks/" title="www.benzinga.com/money/best-financial-services-stocks/">www.benzinga.com/money/best-financial-services-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AGMH

BYFC

CNCK

FNGD

ILLR

LPRO

SHF Holdings, Inc. - Class A Common Stock

SHFS

STEC

12 Financials Stocks Moving In Tuesday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>ECARX Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ECX#NASDAQ">ECX</a>) stock rose 27.9% to $1.08 during Tuesday's regular session. The company's market cap stands at $400.3 million. </li>
<li>QuantaSing Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSG#NASDAQ">QSG</a>) stock increased by 17.01% to $4.54. The company's market cap stands at $232.0 million. </li>
<li>Hesai Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSAI#NASDAQ">HSAI</a>) stock moved upwards by 15.69% to $13.43. The market value of their outstanding shares is at $1.7 billion. </li>
<li>Mingteng International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTEN#NASDAQ">MTEN</a>) shares rose 13.93% to $6.95. The company's market cap stands at $47.5 million. </li>
<li>Golden Heaven Group Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDHG#NASDAQ">GDHG</a>) shares rose 13.86% to $0.31. The market value of their outstanding shares is at $10.6 million. </li>
<li>ThredUp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TDUP#NASDAQ">TDUP</a>) stock rose 13.32% to $3.79. The market value of their outstanding shares is at $430.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>MKDWell Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKDW#NASDAQ">MKDW</a>) shares declined by 29.0% to $0.28 during Tuesday's regular session. The company's market cap stands at $39.6 million. </li>
<li>Jeffs Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFBR#NASDAQ">JFBR</a>) stock fell 26.03% to $0.71. The company's market cap stands at $1.3 million. </li>
<li>Lixiang Education Hldg (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXEH#NASDAQ">LXEH</a>) shares declined by 15.43% to $2.43. The market value of their outstanding shares is at $2.8 million. </li>
<li>ECD Automotive Design (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ECDA#NASDAQ">ECDA</a>) stock fell 14.25% to $0.35. The company's market cap stands at $12.5 million. </li>
<li>Damon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DMN#NASDAQ">DMN</a>) stock fell 11.89% to $0.0. The company's market cap stands at $2.9 million. </li>
<li>Kaixin Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KXIN#NASDAQ">KXIN</a>) stock declined by 9.05% to $0.95. The company's market cap stands at $1.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ECDA

GDHG

HSAI

JFBR

KXIN

LXEH

MKDW

MTEN

TDUP

12 Consumer Discretionary Stocks Moving In Tuesday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Gelteq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GELS#NASDAQ">GELS</a>) stock moved upwards by 236.7% to $3.03 during Tuesday's regular session. The company's market cap stands at $28.5 million. </li>
<li>China SXT Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTC#NASDAQ">SXTC</a>) stock increased by 138.27% to $2.43. The market value of their outstanding shares is at $33.4 million. </li>
<li>Tivic Health Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) stock increased by 121.42% to $7.75. The company's market cap stands at $4.7 million. </li>
<li>Portage Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) stock moved upwards by 58.85% to $14.44. The company's market cap stands at $23.7 million. </li>
<li>Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) shares increased by 30.59% to $0.84. The company's market cap stands at $4.9 million. </li>
<li>Akso Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AHG#NASDAQ">AHG</a>) stock moved upwards by 28.97% to $1.38. The market value of their outstanding shares is at $550.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Vincerx Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VINC#NASDAQ">VINC</a>) shares decreased by 28.0% to $0.1 during Tuesday's regular session. </li>
<li>iBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#NASDAQ">IBIO</a>) stock fell 17.91% to $0.7. The company's market cap stands at $6.8 million. </li>
<li>Scilex Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCLX#NASDAQ">SCLX</a>) shares fell 16.39% to $3.93. The company's market cap stands at $20.5 million. </li>
<li>Y-mAbs Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>) shares fell 13.49% to $4.17. The company's market cap stands at $186.7 million. </li>
<li>Adagio Medical Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADGM#NASDAQ">ADGM</a>) stock declined by 11.56% to $1.06. The company's market cap stands at $16.4 million. </li>
<li>Kala Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KALA#NASDAQ">KALA</a>) shares decreased by 10.64% to $2.94. The company's market cap stands at $17.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADGM

GELS

IBIO

KALA

PRTG

PSTV

SCLX

SXTC

TIVC

VINC

YMAB

12 Health Care Stocks Moving In Tuesday's Intraday Session

<a href="https://www.ncdhhs.gov/news/press-releases/2025/04/22/mpox-found-wastewater-north-carolina-ncdhhs-urges-public-and-providers-be-alert" title="https://www.ncdhhs.gov/news/press-releases/2025/04/22/mpox-found-wastewater-north-carolina-ncdhhs-urges-public-and-providers-be-alert">https://www.ncdhhs.gov/news/press-releases/2025/04/22/mpox-found-wastewater-north-carolina-ncdhhs-urges-public-and-providers-be-alert</a>

SIGA

Watching SIGA Technologies; Shares See Volume To The Upside, Earlier Reports Say NC Department Of Health And Human Services Said Mpox Found In Wastewater In North Carolina From Samples Collected On March 25, March 28 & April 8 From Treatment Plant In Greenville; No Mpox Clade I Cases Have Been Reported To Date

Press Releases

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics

Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics

Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics – PLRX

Pliant Therapeutics Announces Upcoming Presentations at the 2025 American Thoracic Society International Conference

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRX

Comments

Pliant Therapeutics

空売り

Pliant Therapeutics (NASDAQ:PLRX) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル